Background: The aim of this subgroup analysis of the Mabthera International Trial Group study was to evaluate the impact of chemotherapy and rituximab in primary mediastinal B-cell lymphoma (PMBCL) in comparison to other diffuse large B-cell lymphoma (DLBCL).
Primary mediastinal large B-cell lymphoma (PMBCL) was first described in the 1980s [1] and is considered as a distinct entity of diffuse large B-cell lymphoma (DLBCL) representing 2%-4% of non-Hodgkin's lymphomas [2] . In contrast to the more elderly population affected by DLBCL, PMBCL occurs typically in young adults presenting in their third to forth decade of life with a female predominance [3] . The tumor is usually bulky and up to 50% of the patients have signs and symptoms of superior vena cava syndrome. Systemic involvement at diagnosis is rare and most cases are stages I-II. PMBCL tumors show a variable degree of sclerosis, which can explain the frequent persistence of residual masses even after successful treatment. Interestingly, there are clinicopathologic similarities between PMBCL and nodular sclerosis subtype of classical Hodgkin's lymphoma (NScHL). Both entities affect young adults and show the typical localized mediastinal tumor. Moreover, gene expression profiling demonstrated that the molecular signature of PMBCL shares features with NScHL and differs from that of other DLBCL [4, 5] .
In the absence of prospective studies, the optimal treatment of PMBCL is still a matter of debate. Uncertainties exist with regard to the intensity of primary chemotherapy, the role of consolidating involved-field radiotherapy (IFRT), and, most importantly, the impact of an additional treatment with rituximab. In comparison with other DLBCL, PMBCL is characterized by a relatively high proportion of patients with primary disease refractoriness or early relapse after standard CHOP-like induction chemotherapy [6] [7] [8] [9] and poor response to salvage treatment [10] [11] [12] [13] [14] . On the other hand, late relapses after successful first-line therapy are only rarely observed. Because of these characteristics, high efficacy of primary therapy is of key importance for treatment success in PMBCL.
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Therefore, efforts to improve the outcome of PMBCL have focused on strategies of primary chemotherapy dose intensification and radiotherapy consolidation. Several retrospective studies in PMBCL suggested superiority of thirdgeneration regimens, such as MACOP-B, followed by IFRT over CHOP chemotherapy with or without IFRT in terms of response, progression-free survival and overall survival (OS) [11, 12, [15] [16] [17] [18] . An alternative approach for improving response rates and outcome of PMBCL might be the addition of CD20 monoclonal antibody rituximab, which has been shown to substantially increase disease control and survival in a variety of B-cell neoplasms (such as DLBCL, follicular lymphoma, mantle cell lymphoma and chronic lymphocytic leukemia). However, information on the effect of rituximab in PMBCL is sparse. There are two reports in abstract form, suggesting that chemotherapy in combination with rituximab is associated with a better OS and progression-free survival in comparison with regimens without rituximab [19, 20] .
The Mabthera International Trial Group (MInT) trial assessed the role of rituximab in combination with CHOP-like regimens in young patients with good prognosis DLBCL in a prospective randomized phase-III setting. After a median follow-up of 34 months, patients treated with CHOP-like chemotherapy in combination with rituximab had a significant increased 3-year event-free survival (EFS; 79% versus 59%) and OS (93% versus 84%) compared with those assigned to chemotherapy alone [21] . The goal of the present subgroup analysis of the MInT trial was to evaluate the impact of rituximab on the outcome of patients with PMBCL in comparison to other DLBCL.
patients and methods

Patients, diagnostic measures and treatment
Patients and details on treatment within the MInT study have been published previously [21] . In brief, eligible were patients aged 18-60 years with untreated aggressive B-cell lymphoma who had no or one risk factor according to age-adjusted International Prognostic Index (aaIPI) in stages II-IV disease or stage I disease with bulky disease. Patients were randomly assigned to six cycles of CHOP-like (CHOP-21, CHOEP-21, MACOP-B and PMitCEBO) chemotherapy and rituximab or to six cycles of CHOPlike chemotherapy alone. IFRT (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) Gy, according to national standards) was given to sites of primary bulky disease; radiotherapy (30-40 Gy) to sites of primary extranodal disease was given at the physician's discretion.
According to local guidelines and clinical practice in the respective countries, following different definitions in size of bulky disease (minimal diameter of bulky disease mass) was used in the MInT trial: BNLI (British Lymphoma Group) 5.0 cm; Spanish Hospital's Group and Polish Lymphoma Group 7 cm; Danish Lymphoma Group and Swedish Lymphoma Group 10 cm and all other participating groups 7.5 cm. Histological diagnosis was reviewed by an experienced national hemopathologist in every participating country and was available for 99% of patients.
The study was done in accordance with the Helsinki declaration. The protocol was approved by the ethics review committee of every participating center, and all patients gave written informed consent. The trial is registered at ClinicalTrials.gov, number NCT 00064116. The role of the funding source has been described previously [21] .
end points and assessment of response
The primary end point was EFS; secondary end points were complete remission (CR) or unconfirmed complete remission (CRu), progression disease (PD) and OS. EFS was defined as time-to-progressive disease under therapy, the events for which were progressive disease; no achievement of CR or CRu; partial remission; no change; relapse after achievement of CR or CRu or death from any cause, whichever come first.
Response was defined as the proportion of patients with CR or CRu after study treatment of all patients assessable for response. Progression under therapy was defined as the proportion of patients with PD during treatment and within 3 months after the end of treatment of all patients assessable for response. OS was defined as time to death from any cause. Patients without an event in EFS or OS were censored at the last day of having valid information for that end point. Response was assessed according to the International Workshop criteria [22] by the treating physician on day 155 after starting treatment.
statistical analysis
The methods of the primary analysis of this trial have been published previously [21] . EFS and OS were measured from the date of randomization, estimated according to Kaplan-Meier method and compared by log-rank test. Hazard ratios (HRs) were estimated by Cox regression models to investigate independent risk factors for EFS and OS. Categorical data were presented as absolute and relative frequencies and compared by chi-square test or Fisher's exact test, as appropriate. Odds ratios were estimated by logistic regression models. Continuous data were reported as mean 6 standard deviation or median and interquartile range and were tested by t-test for independent groups or Mann-Whitney U test, as suitable. In these exploratory analyses, the level of significance was set to 0.05. Statistical analyses were done with SAS 9.1.3.
results
A total of 824 patients were enrolled in the prospective and randomized MInT study. Patients with missing informed consent form (n = 1) and patients with other kind of lymphoma than DLBCL (n = 109) were excluded from the current analysis, leaving 714 patients assessable for this analysis. Eight-seven patients were identified with PMBCL and 44 (51%) of them were allocated to receive chemotherapy and rituximab. The remaining 627 patients had DLBCL and 315 (50%) were randomized to receive chemotherapy and rituximab.
Patients with PMBCL were younger than those with DLBCL, showed more frequently an elevated lactate dehydrogenase, stage I/II disease, bulky disease, an aaIPI score of 1 and a female predominance (Table 1) .
treatment and response
According to national standards, different CHOP-like regimes (CHOP-21, CHOEP-21, MACOP-B and PMitCEBO) were used in the trial. The vast majority of patients with PMBCL (92%) and DLBCL (92%) were treated with CHOP-21/CHOEP-21 with or without rituximab. In PMBCL 51% and in DLBCL 50% of the patients were allocated to receive rituximab (chemoimmunotherapy). The different regimens were similarly distributed between the both groups (PMBCL and DLBCL) and are listed in Table 2 .
In PMBCL after chemo(immuno)therapy, 31 patients (72%) in the CHOP-like-only arm and 37 patients (84%) treated with rituximab achieved CR or PR, respectively. No patient in the rituximab arm and seven patients in the CHOP-like chemotherapy-only arm had PD. PD was observed after six cycles of chemotherapy in four patients and in three patients after 2, 3 and 4 cycles, respectively (Table 3) .
In a total of 76 (87%) patients with PMBCL, radiotherapy was intended because of bulky disease or extranodal involvement. In PMBCL, there were 39 patients (51%) treated without rituximab and 37 (49%) with rituximab, respectively, who were designated for radiotherapy. Ten patients without rituximab treatment (one patient in PR, six patients with PD and three with unknown remission status) and six patients (two in CR, two in PR, one with NC and the patient who died) in the rituximab arm were not irradiated despite fulfilling the criteria for being eligible for radiotherapy (Table 3 ). There was one patient with CR in the rituximab arm who received radiotherapy though not being eligible according to the protocol. Altogether, 18 of 61 irradiated patients (30%) with PMBCL achieved an improvement in response by radiotherapy. Only four patients (7%) had PD following radiotherapy.
After chemo(immuno)therapy with or without irradiation, 52 of 77 patients with PMBCL (68%) and 442 of 557 patients with DLBCL (79%) achieved CR/CRu. When treated with rituximab, significantly more patients achieved CR/CRu than without rituximab (PMBCL 80% versus 54%, P = 0.015; DLBCL 87% versus 72%, P < 0.001). Without rituximab, significantly more patients with DLBCL achieved a CR/CRu than those with PMBCL (72% versus 54%, P = 0.029), while the difference between PMBCL and DLBCL regarding the CR/CRu rate was no longer significant when rituximab was given (80% versus 87%, P = 0.24).
Treatment with rituximab resulted in a significant reduction of the frequency of PD in PMBCL (2.5% versus 24%, P = 0.006) and in DLBCL (4% versus 10%, P = 0.006), respectively. PD was more frequent in PMBCL than in DLBCL when rituximab was not given (24% versus 10%, P = 0.0095), whereas under treatment with rituximab no difference in PD rate between PMBCL and DLBCL (2.5% versus 3.9%, P = 0.66) was observed. The response after study treatment is listed in Table 4 .
EFS and OS
After a median follow-up of 34 months, there were no differences of EFS {3-year rates: 65% [95% confidence interval (CI) 53% to 75%] versus 71% (95% CI 67% to 75%); log-rank test, P = 0.14} and OS [3-year rates: 83% (95% CI 72% to 90%) versus 89% (95% CI 86% to 91%); log-rank test, P = 0.27] between all patients with PMBCL and all patients with DLBCL, respectively ( Figure 1 ). Of note, only three patients with PMBCL relapsed after achieving CR(u). Two of them within 1 year after randomization (one treated with rituximab and the other without rituximab). The third patient, who was treated with chemotherapy alone, relapsed 42 months after randomization.
Regarding EFS, survival analysis clearly indicates the superiority of additional treatment with rituximab in PMBCL [3-year EFS: 78% (95% CI 61% to 88%) versus 52% (95% CI 35% to 66%); log-rank test, P = 0.012; HR 0.3 (95% CI 0.1-0.8), P = 0.009] and in DLBCL [3-year EFS: 81% (95% CI 76% to 85%) versus 61% (95% CI 55% to 67%); log-rank test, P < 0.0001; HR 0.4 (95% CI 0.3-0.6, P < 0.001)]. EFS was not significantly different comparing PMBCL and DLBCL treated without [3-year EFS: 52% versus 61%; log-rank test, P = 0.13; HR 0.9 (95% CI 0.5-1.5, P = 0.718)] or with rituximab [3-year EFS: 78% versus 81%; log-rank test, P = 0.55; HR 0.9 (95% CI 0.4-1.8), P = 0.740]. Patients with DLBCL showed a better OS when treated with rituximab than without rituximab [3-year OS: 93% (95% CI 89% to 96%) versus 85% (95% CI 80% to 89%); log-rank test P = 0.0005; HR 0.4 (95% CI 0.2--0.7), P < 0.001], whereas the estimated 3-year OS in PMBCL was in the same size and statistically not significant [3-year OS: 88.5% (95% CI 71% to 96%) versus 78.2% (95% CI 61% to 88%); log-rank test, P = 0.16; HR 0.5 (95% CI 0.1-1.6), P = 0.219] (Figure 2 ).
multivariate analyses
In multivariate Cox regression (for survival) and logistic regression (for response) analyses restricted to patients treated with CHOP-21 or CHOEP-21 (n = 657), treatment with rituximab and absence of bulky disease remained predictors for a favorable outcome regarding response, EFS and OS. Moreover, the presence of one risk factor according to aaIPI was associated with a lower CR/CRu rate and an inferior EFS. In contrast, histology (PMBCL versus DLBCL) had no impact on response, EFS and OS, and no interaction of rituximab and histology was observed for the several end points (Table 5) .
discussion
Due to the absence of prospective randomized PBMCL-specific studies, information on clinical characteristics and treatment outcome in comparison with DLBCL is essentially based on retrospective studies. Preliminary findings suggest that patients with PMBCL are younger (median age 36 versus 46 years) than those with DLBCL, that there is a female predominance and that the majority of the patients with PMBCL have stage I/II disease with bulky mediastinal mass [11, [23] [24] [25] [26] [27] . The present subgroup analysis of the MInT trial largely confirms these findings.
In terms of clinical management, experience with CHOP-like chemotherapy indicated that PMBCL has a more aggressive clinical course than DLBCL with a substantial percentage of patients with primary refractory disease or early relapse [28, 29] . Moreover, patients with PMBCL who failed primary treatment seemed to have a substantially worse prognosis than those with DLBCL relapse due to poor efficacy of salvage regimens including high-dose chemotherapy and autologous stem cell transplantation in PMBCL [13, 17, 30] .
The results of this analysis of the MInT study show for the first time prospectively that the CR rate after CHOP-like chemotherapy without rituximab in PMBCL is indeed substantially lower than for DLBCL (54% versus 72%), whereas, conversely, the PD rate in PMBCL is substantially higher than in DLBCL (24% versus 10%). Interestingly, in most cases (seven of nine), PD occurred while still on chemotherapy before a planned radiotherapy could be conducted. Since relapses were virtually absent in PMBCL, but not in DLBCL once CR/CRu was achieved, 3-year EFS of patients with PMBCL, however, was not significantly inferior to that of patients with DLBCL even if rituximab had not been added to primary chemotherapy. The finding that relapses in PMBCL beyond 2 years after initial therapy seem to be a rare event is in accordance with previous reports [17, [30] [31] [32] .
Since PMBCL was highly (but not entirely) correlated with bulky disease and bulky disease has been shown to be a significant outcome predictor (with much stronger impact in the no-rituximab group than in the rituximab group) in a previous analysis of the MInT trial [33] , one might speculate that the inferior response rate of PMBCL compared with DLBCL in the absence of rituximab treatment is due to bulky disease rather than to genuine biological characteristics of the disease itself. Accordingly, bulky disease, but not disease histology, remained as independent EFS and OS predictors in our Cox models. However, the PMBCL-typical treatment failure pattern (high proportion of primary PD but virtual absence of relapse from CR) suggests that the biological peculiarities of PMBCL are not fully explained by excess bulky disease in this entity.
On the other hand, rituximab virtually eliminated primary PD in both PMBCL and DLBCL, thereby increasing CR rates, overall response and EFS significantly for both subsets. This benefit translated into an OS advantage to a similar extent in both entities (DLBCL 93% versus 85% and PMBCL 89% versus 78%), which was, however, not significant in PMBCL due to Figure 2 . EFS, and OS of PMBCL and DLBCL assigned to CHOP-like regimens alone or CHOP-like regimens in combination with rituximab. original article Annals of Oncology the smaller number of patients. No interaction of study treatment and histology was revealed for any end point, again suggesting that rituximab is similarly effective in both entities. Our observation that in PMBCL a benefit in survival occurs when rituximab was added to CHOP-like regimens is in line with two smaller retrospective studies published in abstract form. Dunleavy et al. [19] reported that the addition from rituximab to DA-EPOCH-chemotherapy significantly improved EFS and OS in PMBCL. Avigdor et al. demonstrated an improved PFS in PMBCL caused by addition of rituximab to VACOP-B or CHOP chemotherapy. Furthermore, a superior PFS with VACOP-B compared with CHOP was observed, but this advantage in favor of the more intensive regimen (VACOP-B) was lost after the introduction of rituximab [20] . In contrast, a recently published retrospective study in PMBCL showed no significant differences in terms of CR rate and relapse-free survival after treatment with MACOP-B/VACOP-B with or without an additional treatment with rituximab [34] .
The value of consolidating IFRT in PMBCL is still matter of debate [14, 27] . Our observation that in PMBCL, radiotherapy was able to improve the remission status in 30% of patients irradiated might point to a possible benefit of this strategy; however, it cannot be excluded that this increase of response rates is due to the natural disappearance of masses not containing malignant cells after chemo(immuno)therapy only.
conclusions
The present study shows for the first time in a prospective fashion that rituximab significantly increases response rate and 3-year EFS in PMBCL. This benefit is largely due to virtual elimination of primary PD by rituximab. With rituximab, overall response rate and 3-year EFS of PMBCL are similar to that of DLBCL. Whereas the inferior response rates of PMBCL in comparison to DLBCL in the absence of rituximab seem to be related to bulky disease rather than to histology, the typical treatment failure pattern of PMBCL nevertheless suggests fundamental biological differences to other DLBCL. The combination of rituximab with CHOP chemotherapy is an effective treatment at least in PMBCL with good prognosis features.
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